Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

Share Price is delayed by 15 minutes
Get Live Data
225.50    -3.50 (-1.53%)
Bid:
225.00
Ask:
225.50
Spread: 0.50 (0.222%)
Market Cap: £623.32m
MGAM Live PriceLast checked at - London Stock Exchange

Intraday Morgan Advanced Materials Share Chart

Strategy Update

4 Dec 2025 07:00

RNS Number : 1624K
Morgan Advanced Materials PLC
04 December 2025
 

Press Release

Morgan Advanced Materials plc

4 December 2025

Strategy Update

Unlocking our potential

Morgan Advanced Materials plc, the global leader in advanced ceramics and carbon systems for technologically demanding applications, is today holding a Strategy Update in London. Participation in the event is by invitation only for institutional analysts and investors.

Damien Caby, Chief Executive Officer and Richard Armitage, Chief Financial Officer will host the event. They will present Morgan's strategy for sustainable growth, focussing on:

Transforming our operational effectiveness to turnaround underperforming sites and improve our supply chain effectiveness

Driving stronger growth by focusing on our right to win to enhance our value proposition, strengthening partnerships, and expanding in the right areas to gain share

Maximising our portfolio through partnerships, divestments and bolt-on M&A

They will also set out an updated financial framework and re‐iterate our capital allocation priorities:

Above Market Organic Revenue Growth. We expect to achieve growth in excess of GDP

Attractive Margins. We expect to achieve adjusted operating profit margin of 12% by 2028 with sustainable adjusted operating profit margins of between 12% and 14% beyond 2028

Delivering EPS Growth. Achieving sustained growth in adjusted Earnings per Share, ahead of organic revenue growth, driven by a combination of organic growth, margin accretion, shareholder returns and M&A

Sustaining ROIC. 17% ‐ 20% ROIC

Leverage Range. 1.0x to 1.5x, or up to 2.0x adjusted EBITDA post-acquisition, utilising our strong balance sheet to fund our organic growth, and then over time deploying excess capital to fund incremental M&A or additional shareholder returns as appropriate

Dividend Cover. Shareholder dividends maintained then growing with adjusted earnings at around 2.5x cover

We intend to pause our buy-back programme as part of our focus on balance sheet resilience. The programme will be paused after the completion of the second tranche, by which time we will have purchased £20m of shares.

No new information on current year trading will be shared at the event.

Damien Caby, Chief Executive Officer, commented:

"Morgan is an exciting innovative company with distinctive capabilities and competitive advantages that give us a decisive right to win across our diverse markets. However, we have not been delivering to our ambition or to our full potential. Much of this value can be achieved through more rigorous customer focus and portfolio management. I will set out today a clear strategy focussing on unlocking the Group's potential by focussing on transformation of operational effectiveness, driving stronger growth and the maximisation of portfolio value. This will help us improve the financial performance of the group on a more sustainable basis to deliver against a revised financial framework."

The presentation will be made available at www.morganadvancedmaterials.com at 2pm today, along with a recording of the presentation that will be made available following the event.

 

For further enquiries:

Richard Armitage, CFO

Morgan Advanced Materials

01753 837 000

Nicholas Frost, Investor Relations

 

 

 

 

Nina Coad

Brunswick

0207 404 5959

 

Important notice:

This announcement contains forward-looking statements. These statements have been made in good faith based on the information available up to the time of the approval of this announcement. No assurance can be given that these expectations will prove to have been correct. By their nature, forward-looking statements involve risks, uncertainties or assumptions that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. As such, undue reliance should not be placed on forward-looking statements.

The Directors undertake no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKXLFBELLZFBD
Date   Source Headline
5th Jun 20153:29 pmRNS2014 Environmental, Health and Safety Report
28th May 201511:22 amRNSHolding(s) in Company
20th May 20157:00 amRNSTrading Update
8th May 20153:51 pmRNSResult of AGM
16th Apr 20154:14 pmRNSDirector/PDMR Shareholding
2nd Apr 20158:40 amRNSDirector/PDMR Shareholding
31st Mar 20153:18 pmRNSHolding(s) in Company
31st Mar 20153:14 pmRNSDirector/PDMR Shareholding
31st Mar 201510:12 amRNSPublication of 2014 Annual Report
27th Mar 20159:41 amRNSDirector/PDMR Shareholding
26th Mar 20152:37 pmRNSDirector/PDMR Shareholding
25th Mar 20152:33 pmRNSDirector/PDMR Shareholding
24th Mar 20151:42 pmRNSDirector/PDMR Shareholding
24th Mar 20151:36 pmRNSDirector/PDMR Shareholding
2nd Mar 201512:32 pmRNSDirector/PDMR Shareholding
26th Feb 20152:05 pmRNSDirector/PDMR Shareholding
12th Feb 20157:00 amRNSFY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2014
30th Jan 20157:00 amRNSAppointment of Chief Executive Officer
23rd Dec 20142:03 pmRNSStatement under s.430 (2B) Companies Act 2006
23rd Dec 20142:00 pmRNSStatement under s. 430(2B) Companies Act 2006
18th Dec 201412:08 pmRNSHolding(s) in Company
18th Dec 201412:00 pmRNSDirector/PDMR Shareholding
16th Dec 201410:05 amRNSBlocklisting Interim Review
12th Dec 20141:05 pmRNSBoard Changes
3rd Dec 201410:47 amRNSDirector/PDMR Shareholding
1st Dec 20148:49 amRNSRejection of Vesuvius Proposal
1st Dec 20147:00 amRNSStatement of intention not to make an offer
11th Nov 20147:00 amRNSTrading Update
17th Oct 201410:17 amRNSMorgan Advanced Matereals - CDP Announcement
14th Oct 20149:29 amRNSHolding(s) in Company
2nd Oct 201411:25 amRNSDirector/PDMR Shareholding
29th Sep 20147:00 amRNSBoard Change
23rd Sep 20149:42 amRNSHolding(s) in Company
22nd Aug 201410:59 amRNSHolding(s) in Company
18th Aug 201410:16 amRNSHalf Yearly Report
5th Aug 20149:53 amRNSUNIVERSITY OF MANCHESTER PARTNERS WITH MORGAN
1st Aug 20149:18 amRNS£15m Composites & Defence Systems Contract Award
31st Jul 20142:13 pmRNSDirector/PDMR Shareholding
23rd Jul 20147:00 amRNSHalf Year Results
18th Jul 20149:25 amRNSDirector Declaration
15th Jul 20147:00 amRNSAcquisition of Porextherm Dämmstoffe GmbH
14th Jul 20149:15 amRNSDirector Declaration
18th Jun 20148:16 amRNSChange of Directors' responsibilities
16th Jun 201412:01 pmRNSBlocklisting Interim Review
9th Jun 20143:10 pmRNSHolding(s) in Company
9th Jun 201412:28 pmRNSAcquisition of Porextherm Dämmstoffe GmbH
9th Jun 201410:39 amRNSDirector/PDMR Shareholding
9th May 20143:39 pmRNSResult of AGM
9th May 20147:00 amRNSInterim Management Statement
9th Apr 201410:42 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.